UBE2O remodels the proteome during terminal erythroid differentiation

Abstract
During terminal differentiation, the global protein complement is remodeled, as epitomized by erythrocytes, whose cytosol is ~98% globin. The erythroid proteome undergoes a rapid transition at the reticulocyte stage; however, the mechanisms driving programmed elimination of preexisting cytosolic proteins are unclear. We found that a mutation in the murine Ube2o gene, which encodes a ubiquitin-conjugating enzyme induced during erythropoiesis, results in anemia. Proteomic analysis suggested that UBE2O is a broad-spectrum ubiquitinating enzyme that remodels the erythroid proteome. In particular, ribosome elimination, a hallmark of reticulocyte differentiation, was defective in Ube2o−/− mutants. UBE2O recognized ribosomal proteins and other substrates directly, targeting them to proteasomes for degradation. Thus, in reticulocytes, the induction of ubiquitinating factors may drive the transition from a complex to a simple proteome.
Funding Information
  • National Institutes of Health (award313215, R01 DK61692)
  • National Heart, Lung, and Blood Institute (award302896, 5R21HL116210)
  • National Heart, Lung, and Blood Institute (award302897, 5R01HL125710)
  • National Heart, Lung, and Blood Institute (award302898, F30HL124980)
  • Biogen (award313216)
  • National Institute of Diabetes and Digestive and Kidney Diseases (award312802, R01 DK087992)
  • Biogen Idec (award312803, NA)
  • National Institute of Diabetes and Digestive and Kidney Diseases (award302900, 5K01DK098285)
  • National Institute of General Medical Sciences (award302899, T32GM007753)